Article

Transglutaminase antibodies in children with a genetic risk for celiac disease.

Section of Pediatric Gastroenterology, Hepatology, and Nutrition, Center for Pediatric Inflammatory Bowel Diseases, Department of Pediatrics, Barbara Davis Center for Childhood Diabetes, Denver, Colorado, USA.
Journal of Pediatrics (Impact Factor: 3.74). 09/2000; 137(3):356-60. DOI: 10.1067/mpd.2000.107582
Source: PubMed

ABSTRACT The transglutaminase (TG) antibody test is accurate in identifying celiac disease in symptomatic children. We sought to determine the positive predictive value of this test in asymptomatic children at genetic risk for celiac disease.
Asymptomatic children with a genetic risk for celiac disease were studied to investigate the relationships between TG antibody titer, small bowel histology, growth, and clinical features. Small bowel biopsy histology was graded by using the system of Marsh.
Of 30 children with a positive TG antibody test result, 21 (70%) had definite (Marsh score 2 or 3) and 4 (13%) had possible (Marsh score 1) biopsy evidence of celiac disease. TG antibody titer correlated with Marsh score (r = 0.569, P <.01). There was an inverse correlation between Marsh score and height z score (r = -0.361, P =. 05).
In this group of asymptomatic children screened because of a genetic risk, TG antibodies have a positive predictive value of 70% to 83% for biopsy evidence of celiac disease and may identify children before clinical features of celiac disease develop.

0 Followers
 · 
74 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The presence of HLA haplotype DR3-DQ2 or DR4-DQ8 is associated with an increased risk of celiac disease. In addition, nearly all children with celiac disease have serum antibodies against tissue transglutaminase (tTG).
    New England Journal of Medicine 07/2014; 371(1):42-9. DOI:10.1056/NEJMoa1313977 · 54.42 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Many studies have shown that the prevalence of celiac disease (CD) is increasing in the patients with irritable bowel syndrome (IBS), but the present evidences are controversy and all of the researches don’t suggest evaluation of the patients with IBS for the CD. Methods: In the cross-sectional study, 1000 patients that affected by IBS with the predominant feature of diarrhea who referred to the gastroenterology clinic were evaluated during 2009-2012 years. Blood samples were taken from the patients for ELISA of IgA tissue transglutaminase (TTG) Ab. Then biopsy was taken from the second part of duodenum of all of patients by endoscopy and the sample was referred to pathologist for histopathology evaluation in order to confirm diagnosis. Results: About half of the patients with IBS were women (50.3%) and the mean age ± Standard deviation of the men and women was 29.59±11.41 and 28.42±11.73, respectively. The mean titer of TTG IgA Ab in the women and men affected by IBS was 5.25±17.77 and 7.22±25.4, respectively. 76 cases (7.6%) that affected by IBS had high serum level of Ab titer (TTG IgA.Ab = 10) that including 41 women and 35 men. In the patients with high serum level of Ab titer, 57 cases (75%) were affected by celiac disease (based on histopathology report). Therefore, the prevalence of CD was 5.7% among patients with IBS. Conclusion: In the current study the incidence of CD was evaluated 5.7 cases per each 100 people with IBS. It’s suggested that all of the patients with diarrhea predominant IBS and high serum level of TTG IgA Ab must be examined for evaluation of CD.
    Journal of Clinical and Diagnostic Research 12/2014; 8(12):1-3. DOI:10.7860/JCDR/2014/10175.5286 · 0.13 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: 1. Overview of Biomarkers for Diagnosis and Monitoring of Celiac Disease 2. Cystatin C: A Kidney Function Biomarker 3. Procalcitonin: Potential Role in Diagnosis and Management 4. Manganese Superoxide Dismutase and Oxidative Stress Modulation 5. Selenium and Selenium-Dependent Antioxidants in Chronic Kidney Disease 6. Lipidomics:New Insight Into Kidney Disease
    Advances in clinical chemistry 02/2015; 68. · 4.30 Impact Factor